Simon Sturge - 05 Jun 2025 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Reporting relationship: Director
Issuer ticker: MLTX
Reported as of: 05 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2025, 09:08:48 UTC
Prior SEC filing: 08 Oct 2024
Source filing: View source filing
Reporting owner signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Simon Sturge

Key filing fact

Simon Sturge filed Form 4 for MoonLake Immunotherapeutics (MLTX) on 09 Jun 2025.

Key facts

This page summarizes Simon Sturge's Form 4 filing for MoonLake Immunotherapeutics (MLTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2025, 09:08.

Change

Previous filing in this sequence was filed on 08 Oct 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001920785 Primary reporting owner

Sturge Simon

Relationship: Director
Address: C/O MOONLAKE IMMUNOTHERAPEUTICS, DORFSTRASSE 29, ZUG, SWITZERLAND
Signature: /s/ Matthias Bodenstedt, Attorney-in-fact for Simon Sturge
Signature date: 09 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MLTX transaction Derivative

Option to Buy

Award

Transaction value: $0
Shares: +6,682
Change %
Price: $0.000000
Shares after: 6,682
Date: 05 Jun 2025
Ownership: Direct
Underlying class: Class A ordinary shares, par value $0.0001 per share
Underlying amount: 6,682
Exercise price: $48.83
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.